Clinical trials: Vascular Conditions
Wegeners Granulomatosis
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive…
- Trial name
- SPARROW (NCT01446211)
- Testing
- Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
- Where
- Czechia
- Volunteers
- 4 people
- Sponsor
- Nordic Pharma SAS
Acute Myelogenous Leukemia, Multiple Myeloma
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.
- Conditions
- Acute Myelogenous Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma
- Trial name
- (ANSWer) (NCT04014764)
- Testing
- This is a non-interventional study
- Where
- 20 sites in United States, Greece and 1 more
- Volunteers
- 119 people
- Sponsor
- Notable Labs
Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable…
- Trial name
- TBRIDGE-CV (NCT07487363)
- Testing
- TB-500
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hudson Biotech
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Memory Disorders, Alzheimer Disease
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
The proposed study is designed to evaluate the performance of the COGNISION™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment
- Trial name
- COGNISION™ (NCT00938665)
- Testing
- COGNISION™ System
- Where
- 7 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Neuronetrix, Inc.
Ischemic Heart Disease, Coronary Microvascular Disease
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no…
- Conditions
- Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia
- Trial name
- MICRO2 (NCT06212466)
- Testing
- CardioFlux
- Where
- 8 sites in United States
- Volunteers
- 136 people
- Sponsor
- Genetesis Inc.
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria (CSU)
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily [b.i.d.] by mouth [p.o.]) compared to dupilumab (600 mg loading dose administered…
- Trial name
- RECLAIM (NCT06868212)
- Testing
- Remibrutinib, Dupilumab
- Where
- 121 sites in United States
- Volunteers
- 409 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Reperfusion Injury
Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury
The current study aims to evaluate different doses of PC-SOD injections for efficacy and safety in comparison to placebo, in order to provide a basis for future clinical trials in terms of experimental design and dose selection.
- Trial name
- NCT03995732
- Testing
- PC-SOD
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Multiple Myeloma
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination with BMS-986405 in participants with relapsed and…
- Trial name
- NCT04036461
- Testing
- CC-99712, BMS-986405
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 47 people
- Sponsor
- Celgene
Angina Pectoris
Neurostimulation to Treat Refractory Angina Pectoris Pain
The therapy under investigation involves an implanted Medtronic neurostimulation system to relieve symptoms of angina pectoris pain.
- Trial name
- STARTSTIM (NCT00200070)
- Testing
- Spinal Cord Stimulation
- Where
- 8 sites in United States, Canada
- Volunteers
- 228 people
- Sponsor
- MedtronicNeuro
Coronary Artery Disease, Angina Pectoris
An Evaluation of Rigid Sternal Fixation in Supporting Bone Healing and Improving Postoperative Recovery
The primary objective of this study is to evaluate sternal bone healing following a full median sternotomy versus standard of care for sternal closure with wire cerclage.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Cardiac Valve Disease
- Trial name
- SB (NCT01783483)
- Testing
- SternaLock Blue closure system, Suture Wire
- Where
- 12 sites in United States
- Volunteers
- 236 people
- Sponsor
- Zimmer Biomet
Angina Pectoris, Coronary Heart Disease
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled…
- Conditions
- Angina Pectoris, Coronary Heart Disease, X Syndrome, Angina, Non Obstructive Coronary Artery Disease
- Trial name
- NCT04984954
- Testing
- MUSK pill
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Multiple Myeloma
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
This is an open-label, multicenter study to confirm the safety and efficacy of durvalumab + daratumumab (D2) in subjects with relapsed and refractory multiple myeloma.
- Trial name
- FUSIONMM-003 (NCT02807454)
- Testing
- Daratumumab, Durvalumab, Pomalidomide
- Where
- 64 sites in United States, Belgium and 7 more
- Volunteers
- 37 people
- Sponsor
- Celgene
Aortic Valve Disease
Post Market Clinical Follow-Up Study in Patients Treated With the On-X Ascending Aortic Prosthesis (AAP)
The ASCEND post-market clinical follow-up study is undertaken to evaluate safety and clinical performance of the On-X Ascending Aortic Prosthesis (AAP) used in surgical aortic valve replacement.
- Trial name
- ASCEND (NCT05082454)
- Testing
- Open repair
- Where
- 11 sites in United States, Germany and 3 more
- Volunteers
- 108 people
- Sponsor
- JOTEC GmbH
Cryopyrin Associated Periodic Syndrome
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
ZYIL1 is expected to show benefit in patients with CAPS. The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with CAPS.
- Trial name
- NCT05186051
- Testing
- ZYIL1 capsule
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- Zydus Lifesciences Limited
Hydrocephalus, Hydrocephalus in Children
A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)
Aqueduct's Smart External Drain (SED) will be compared to the current gold standard for temporary CSF management in a hospital setting.
- Conditions
- Hydrocephalus, Hydrocephalus in Children, Tumor, Brain, Subarachnoid Hemorrhage
- Trial name
- NCT03471702
- Testing
- Smart External Drain - SED
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aqueduct Critical Care
Relapsed/Refractory, Multiple Myeloma
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone…
- Trial name
- NCT03439280
- Testing
- Mezagitamab, Pomalidomide, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Spontaneous Urticaria (CSU)
A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
The goal of this clinical trial is to evaluate the rapid onset characteristics of TLL-018 in moderate-to-severe CSU with inadequate response to second-generation H1 antihistamines.
- Trial name
- NCT07665996
- Testing
- TLL-018
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.